Breaking News Instant updates and real-time market news.

EIGR

Eiger BioPharmaceuticals

$11.85

0.9 (8.22%)

, MRK

Merck

$59.76

0.58 (0.98%)

07:33
05/17/18
05/17
07:33
05/17/18
07:33

Eiger BioPharmaceuticals price target raised to $53 from $36 at Wedbush

Wedbush analyst Liana Moussatos raised her price target for Eiger BioPharmaceuticals (EIGR) to $53 from $36 after the company expanded its licensing agreement with Merck (MRK) to include Hutchinson-Gilford Progeria Syndrome, or progeria, a fatal premature aging disease for which there are no approved drugs, after publication on April 24 in the Journal of the American Medical Association of Phase 2 results demonstrating a survival benefit -- after 2.2 years, only 1 of 27 lonafarnib-treated progeria syndrome patients died compared to 9 of 27 of untreated patients. In a research note to investors, Moussatos, who has an Outperform rating on shares, said that Eiger now has worldwide rights for progeria, HDV and all lonafarnib indications is a "game-changer" for the company.

EIGR

Eiger BioPharmaceuticals

$11.85

0.9 (8.22%)

MRK

Merck

$59.76

0.58 (0.98%)

  • 05

    Jun

  • 23

    Oct

EIGR Eiger BioPharmaceuticals
$11.85

0.9 (8.22%)

01/16/18
JEFF
01/16/18
NO CHANGE
Target $26
JEFF
Buy
Eiger selloff on failed study an overreaction, says Jefferies
Jefferies analyst Maury Raycroft views the selloff today in shares of Eiger BioPharmaceuticals as an overreaction. The analyst notes that his model did not include pulmonary arterial hypertension, which failed this morning in a Phase II trial. He viewed the Liberty study as a "promising" with high reward potential, however. Nevertheless, Raycroft sees multiple near-term catalysts to drive Eiger shares. He reiterates a Buy rating on the stock with a $26 price target.
03/21/18
PIPR
03/21/18
NO CHANGE
Target $17
PIPR
Overweight
Piper remains buyer of Eiger after FDA agrees to single Phase III trial
Piper Jaffray analyst Edward Tenthoff says he remains a buyer of Eiger BioPharmaceuticals after the FDA agreed to a single, pivotal Phase III trial of Sarasar in 300 hepatitis delta virus patients. The stock is down year-to-date due to a Phase II pulmonary arterial hypertension failure, but Eiger remains the in a leadership position in HDV, Tenthoff tells investors in a research note. He reiterates an Overweight rating on the shares with a $17 price target.
05/09/18
RILY
05/09/18
INITIATION
Target $24
RILY
Buy
Eiger BioPharmaceuticals initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Eiger BioPharmaceuticals with a Buy rating and $24 price target. The analyst has "reasonable conviction" in the opportunity for the company's hepatitis and virus franchise.
05/09/18
05/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cleveland-Cliffs (CLF) initiated with a Buy at Seaport Global. 2. Amneal Pharmaceuticals (AMRX) initiated with a Buy at Deutsche Bank. 3. Iridium (IRDM) initiated with a Buy at BWS Financial. 4. ServiceMaster (SERV) initiated with a Buy at Buckingham while Rollins (ROL) was initiated with a Neutral at Buckingham. 5. Eiger BioPharmaceuticals (EIGR) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MRK Merck
$59.76

0.58 (0.98%)

04/25/18
DBAB
04/25/18
NO CHANGE
DBAB
Hold
Merck may need to reassess animal health unit, says Deutsche Bank
While Merck (MRK) describes its animal health unit as a key growth driver and an important part of the company, it remains to be seen whether investors will continue to accept this as a reason for the business to remain within the company, Deutsche Bank analyst Gregg Gilbert tells investors in a research note. He believes the unit is potentially undervalued. Given Zoetis' (ZTS) success as a company and a stock, and Eli Lilly's (LLY) ongoing review of strategic options for its Elanco Animal Health business, Gilbert conducted a preliminary separation analysis of Merck's animal health unit. The analysis suggests that a separation could be meaningfully accretive to earnings. The analyst keeps a Hold rating on Merck.
04/26/18
BMOC
04/26/18
NO CHANGE
Target $70
BMOC
Outperform
Merck price target raised to $70 from $65 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Merck to $70 and kept his Outperform rating, forecasting a "mixed to net-positive" Q1 earnings report. The analyst notes the focus will likely fall on the core Keytruda and Januvia franchises as he raises his peak sales estimate for the former to $13B from $12B after KN-189 data, which he expects to be further supported by discussions at ASCO.
05/10/18
STFL
05/10/18
NO CHANGE
STFL
Hold
Exelixis pullback may create interesting entry point, says Stifel
After Exelixis (EXEL) and partner Roche (RHHBY) announced the Phase 3 IMblaze370 trial did not achieve statistical-significance on the primary efficacy endpoint evaluating the ability of a combination of a MEK inhibitor and anti-PD-L1 to improve overall survival in patients with microsatellite stable metastatic colorectal cancer, Stifel analyst Stephen Willey said he believes attrition in Exelixis shares might create an interesting entry point. The failure of IMblaze370 removes some of Exelixis' longer-term optionality and he expects topics of RCC growth/competition, label expansion, and longer-term cabozantinib exclusivity to remain core to the story going forward, said Willey who has a Hold rating on the stock. Array BioPharma (ARRY) also has Phase 1/2 development collaborations in place with both Bristol-Myers (BMY) and Merck (MRK) evaluating the MEK/PD-1 hypothesis in earlier-lines of MSS mCRC, noted Willey, who said he would "be opportunistic" on any weakness in its shares. He maintains a Buy rating on Array, which is down 5% in pre-market trading.
05/16/18
SPHN
05/16/18
INITIATION
Target $16
SPHN
Overweight
Codexis initiated with an Overweight at Stephens
Stephens analyst Drew Jones started Codexis (CDXS) with an Overweight rating and $16 price target, stating that the company's CodeEvolver platform technology has been sought by pharma partners Merck (MRK), GlaxoSmithKline (GSK) and Nestle (NSRGY) and he expects continued deeper adoption from other major industry players.

TODAY'S FREE FLY STORIES

VKTX

Viking Therapeutics

$19.47

9.07 (87.21%)

08:28
09/19/18
09/19
08:28
09/19/18
08:28
Recommendations
Viking Therapeutics analyst commentary  »

Viking Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ZEAL

Zealand Pharma

$18.48

0.4 (2.21%)

, NVO

Novo Nordisk

$47.44

-0.2 (-0.42%)

08:27
09/19/18
09/19
08:27
09/19/18
08:27
Recommendations
Zealand Pharma, Novo Nordisk analyst commentary  »

Zealand Pharma price…

ZEAL

Zealand Pharma

$18.48

0.4 (2.21%)

NVO

Novo Nordisk

$47.44

-0.2 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLK

Westlake Chemical

$83.89

-1.82 (-2.12%)

08:26
09/19/18
09/19
08:26
09/19/18
08:26
Downgrade
Westlake Chemical rating change  »

Westlake Chemical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALLK

Allakos

$44.88

0.95 (2.16%)

08:25
09/19/18
09/19
08:25
09/19/18
08:25
Conference/Events
William Blair biotech analysts to hold an analyst/industry conference call »

Biotech Analysts, along…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

SPWR

SunPower

$7.55

0.97 (14.74%)

, ENPH

Enphase Energy

$4.35

0.48 (12.40%)

08:24
09/19/18
09/19
08:24
09/19/18
08:24
Recommendations
SunPower, Enphase Energy, First Solar analyst commentary  »

Tariff exemption a…

SPWR

SunPower

$7.55

0.97 (14.74%)

ENPH

Enphase Energy

$4.35

0.48 (12.40%)

FSLR

First Solar

$49.56

1.81 (3.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

08:23
09/19/18
09/19
08:23
09/19/18
08:23
Conference/Events
JPMorgan to hold a summit »

India Investor Summit…

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:21
09/19/18
09/19
08:21
09/19/18
08:21
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:20
09/19/18
09/19
08:20
09/19/18
08:20
General news
Senate Judiciary vote on Kavanaugh Supreme Court vote cancelled, CNN reports »

The Senate Judiciary…

$DJU

DJ Utility Average

$0.00

(0.00%)

08:20
09/19/18
09/19
08:20
09/19/18
08:20
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OKTA

Okta

$69.82

0.3 (0.43%)

, ZS

Zscaler

$39.79

-0.455 (-1.13%)

08:20
09/19/18
09/19
08:20
09/19/18
08:20
Conference/Events
William Blair to hold a tour »

Cybersecurity Bus Tour…

OKTA

Okta

$69.82

0.3 (0.43%)

ZS

Zscaler

$39.79

-0.455 (-1.13%)

PANW

Palo Alto Networks

$234.07

2.1 (0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 03

    Oct

  • 04

    Oct

  • 05

    Oct

  • 10

    Oct

  • 11

    Oct

  • 16

    Oct

  • 06

    Dec

  • 10

    Dec

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:20
09/19/18
09/19
08:20
09/19/18
08:20
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$207.47

0.89 (0.43%)

08:20
09/19/18
09/19
08:20
09/19/18
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:20
09/19/18
09/19
08:20
09/19/18
08:20
General news
U.S. housing starts preview: »

U.S. housing starts…

08:20
09/19/18
09/19
08:20
09/19/18
08:20
General news
U.S. current account preview: »

U.S. current account…

XLK

Technology Select Sector SPDR

$74.46

0.45 (0.61%)

08:19
09/19/18
09/19
08:19
09/19/18
08:19
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$74.89

0.52 (0.70%)

08:19
09/19/18
09/19
08:19
09/19/18
08:19
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$116.98

1.5 (1.30%)

08:19
09/19/18
09/19
08:19
09/19/18
08:19
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$59.68

0.065 (0.11%)

08:19
09/19/18
09/19
08:19
09/19/18
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$54.37

-0.11 (-0.20%)

08:18
09/19/18
09/19
08:18
09/19/18
08:18
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$54.72

-0.25 (-0.45%)

08:18
09/19/18
09/19
08:18
09/19/18
08:18
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWKS

Skyworks

$86.82

0.58 (0.67%)

08:18
09/19/18
09/19
08:18
09/19/18
08:18
Recommendations
Skyworks analyst commentary  »

Skyworks underperformance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$93.71

0.5 (0.54%)

08:18
09/19/18
09/19
08:18
09/19/18
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIVB

Civista Bancshares

$22.95

-0.23 (-0.99%)

08:18
09/19/18
09/19
08:18
09/19/18
08:18
Upgrade
Civista Bancshares rating change  »

Civista Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$170.24

0.68 (0.40%)

08:18
09/19/18
09/19
08:18
09/19/18
08:18
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIA

Diamonds Fund ETF

$262.87

1.89 (0.72%)

08:17
09/19/18
09/19
08:17
09/19/18
08:17
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.